ChiCTR2500101064 版本V1.0 版本创建时间2025/04/18 15:15:00 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500101064 

最近更新日期:

Date of Last Refreshed on:

2025-04-18 15:14:50 

注册时间:

Date of Registration:

2025-04-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

美国临床医生报告的颏下脂肪评分量表在中国有效性和适用性的验证及中国临床医生报告的颏下脂肪评分量表制作

Public title:

Validation of the Effectiveness and Applicability in China of the Submental Fat Rating Scale Reported by American Clinicians, and Development of a Submental Fat Rating Scale Reported by Chinese Clinicians

注册题目简写:

English Acronym:

研究课题的正式科学名称:

美国临床医生报告的颏下脂肪评分量表在中国有效性和适用性的验证及中国临床医生报告的颏下脂肪评分量表制作

Scientific title:

Validation of the Effectiveness and Applicability in China of the Submental Fat Rating Scale Reported by American Clinicians, and Development of a Submental Fat Rating Scale Reported by Chinese Clinicians

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李玮 

研究负责人:

龙笑 

Applicant:

Wei Li 

Study leader:

Xiao Long 

申请注册联系人电话:

Applicant telephone:

+86 135 2046 4757

研究负责人电话:

Study leader's
telephone:

+86 10 8806 8177

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liwei@imeik.com

研究负责人电子邮件:

Study leader's E-mail:

pumclongxiao@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区建国路世茂大厦 C 座 22 层

研究负责人通讯地址:

北京市西城区大木仓胡同 41 号

Applicant address:

22nd Floor, Tower C, Shimao Building, Jianguo Road, Chaoyang District, Beijing

Study leader's address:

No. 41, Damucang Hutong, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京诺博特生物科技有限公司

Applicant's institution:

Beijing Nuobote Biotechnology Co., Ltd.

研究负责人所在单位:

中国医学科学院北京协和医院

Affiliation of the Leader:

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

I-25PJ0242

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医学科学院北京协和医院伦理审查委员会

Name of the ethic committee:

The Ethics Review Committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2025-01-20 00:00:00

伦理委员会联系人:

李佳月

Contact Name of the ethic committee:

Li Jiayue

伦理委员会联系地址:

北京东城区帅府园1号

Contact Address of the ethic committee:

No. 1, Shuaifu Yuan, Dongcheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6915 6874

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医学科学院北京协和医院

Primary sponsor:

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

研究实施负责(组长)单位地址:

北京市西城区大木仓胡同 41 号

Primary sponsor's address:

No. 41, Damucang Hutong, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

北京

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

北京诺博特生物科技有限公司

具体地址:

北京市昌平区科技园区双营西路79号院6号楼6层

Institution
hospital:

Beijing Nuobote Biotechnology Co., Ltd.

Address:

Building 6, No. 6, Courtyard 79, Shuangying West Road, Science and Technology Park, Changping District, Beijing

经费或物资来源:

申办者

Source(s) of funding:

Sponsor

研究疾病:

颏下脂肪堆积  

Target disease:

Submental fat accumulation

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例研究 

Study design:

Case study 

研究目的:

验证美国临床医生报告的颏下脂肪评分量表(CR-SMFRS)在中国的有效性和适用性,并制作中国临床医生报告的颏下脂肪评分量表(CR-SMFRS)。  

Objectives of Study:

To validate the effectiveness and applicability in China of the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) reported by American, and to develop a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) for Chinese.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18周岁,中国男性或女性; 2.皮肤的Fitzpatrick分型III至IV级(分型标准见附录2); 3.自愿参加此项临床试验,能够签署知情同意书并能够接受临床试验照片拍摄者。

Inclusion criteria

1.Age >= 18 years old, Chinese male or female; 2.Having a Fitzpatrick skin type ranging from III to IV (refer to Appendix 2 for the classification criteria); 3.Willing to participate in this clinical trial, capable of signing the informed consent form, and able to accept having clinical trial photographs taken.

排除标准:

1.下面部、颈部及照相区域的肩部有明显先天或外伤畸形; 2.下面部、颈部及照相区域的肩部有明显组织缺损或瘢痕; 3.下面部、颈部及照相区域的肩部有纹身、穿孔、或其他明显的个人特征; 4.下面部、颈部及照相区域的肩部在筛选前 6 个月内进行过肉毒素注射、12 个月内进行过填充剂注射等治疗,且在拍照前有相应的治疗计划; 5.下面部、颈部周围的淋巴结病或可能影响评估的其他任何疾病; 6.下面部区域有胡须且不能接受拍照时剔除胡须的受试者; 7.由研究者判定不适宜入选或有其他原因不宜入选的受试者。

Exclusion criteria:

1.Visible congenital or traumatic deformities in the lower face, neck, and shoulder area within the photographic region; 2.Noticeable tissue defects or scars in the lower face, neck, and shoulder area within the photographic region; 3.Tattoos, piercings, or other distinct personal characteristics in the lower face, neck, and shoulder area within the photographic region; 4.Administration of botulinum toxin injections within the past 6 months or filler injections within the past 12 months in the lower face, neck, and shoulder area within the photographic region, with corresponding treatment plans prior to photography; 5.Lymphadenopathy around the lower face and neck or any other condition that may affect the assessment; 6.Subjects with facial hair in the lower face region who are unwilling to have it removed for photography; 7.Subjects deemed unsuitable for inclusion by the investigator or those unsuitable for inclusion due to other reasons.

研究实施时间:

Study execute time:

From 2025-04-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-04-18 00:00:00 To 2025-07-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

120

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

北京 

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

中国医学科学院北京协和医院 

单位级别:

三甲 

Institution
hospital:

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

指标类型:

主要指标

Outcome:

None

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-04-18 15:14:50